Australian Super Pty LTD Biogen Inc. Transaction History

Australian Super Pty LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 28, 2023	BUY	$275.25 - $318.06 $500,679 - $578,551	1,819 New	1,819 $518,000
Q1 2022 Apr 29, 2022	SELL	$193.77 - $244.14 $37.2 Million - $46.8 Million	-191,861 Closed	0 $0
Q4 2021 Jan 24, 2022	SELL	$223.92 - $287.77 $14.1 Million - $18.2 Million	-63,136 Reduced 24.76%	191,861 $46.4 Million
Q3 2021 Nov 12, 2021	SELL	$282.99 - $369.05 $4.96 Million - $6.46 Million	-17,516 Reduced 6.43%	254,997 $72.2 Million
Q2 2021 Aug 12, 2021	SELL	$259.0 - $414.71 $60.9 Million - $97.6 Million	-235,266 Reduced 46.33%	272,513 $94.4 Million
Q1 2021 May 14, 2021	BUY	$242.95 - $284.63 $89.5 Million - $105 Million	368,303 Added 264.06%	507,779 $142 Million
Q4 2020 Feb 11, 2021	BUY	$236.26 - $355.63 $33 Million - $49.6 Million	139,476 New	139,476 $34.2 Million

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Australian Super Pty LTD, based on Form 13F filings with the SEC.

Stay updated on Australian Super Pty LTD with notifications on news.